519 filings
ARS
2023 FY
IOVA
Iovance Biotherapeutics Inc
1 May 24
Annual report to shareholders
5:05pm
DEFA14A
IOVA
Iovance Biotherapeutics Inc
29 Apr 24
Additional proxy soliciting materials
5:07pm
DEF 14A
IOVA
Iovance Biotherapeutics Inc
Definitive proxy
29 Apr 24
5:06pm
8-K
IOVA
Iovance Biotherapeutics Inc
3 Apr 24
Other Events
5:15pm
8-K
IOVA
Iovance Biotherapeutics Inc
29 Mar 24
Departure of Directors or Certain Officers
5:00pm
8-K
ep64j
4 Mar 24
Iovance Biotherapeutics Announces FDA has Lifted Clinical Hold on the IOV-LUN-202 Registrational Trial in Non-Small Cell Lung Cancer
8:00am
8-K
t8rwhvi
29 Feb 24
Other Events
7:30am
8-K
93hdofv5
28 Feb 24
Iovance Biotherapeutics Reports Fourth Quarter and Full Year 2023
4:05pm
8-K
yfvf uwt94h5c1c
22 Feb 24
Other Events
4:53pm
424B5
m81 mo8cze
21 Feb 24
Prospectus supplement for primary offering
4:44pm
8-K
co3y50q6r
20 Feb 24
Iovance Biotherapeutics, Inc. Announces Pricing of $211 Million Underwritten Offering of Common Stock
5:23pm
8-K
udz6o
20 Feb 24
Iovance’s AMTAGVITM (lifileucel) Receives U.S. FDA Accelerated Approval
6:03am
8-K
lz2ijqjmw nrynzt8
26 Jan 24
Other Events
12:00am
8-K
d93qv q6m8wbglk06a48
8 Jan 24
Other Events
5:03pm
8-K
mgqaakv28chjpwpbt0
27 Dec 23
Iovance Biotherapeutics Announces Clinical Program Update for LN-145 in Non-Small Cell Lung Cancer
5:00pm
UPLOAD
rvt5ijd7heeol33
21 Nov 23
Letter from SEC
12:00am
CORRESP
rg2zyg d93g10trt6d
17 Nov 23
Correspondence with SEC
12:00am
8-K
5iz5 tqx8npelu4
7 Nov 23
Iovance Biotherapeutics Reports Third Quarter and Year-to-Date 2023
4:05pm